NCT03529422View on ClinicalTrials.gov

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 7, 2019

Primary Completion Date

July 1, 2024

Study Completion Date

May 6, 2026

Conditions
LarynxLipOral CancerDigestive Organs--Diseases
Interventions
DRUG

Durvalumab

Durvalumab 1500mg IV every 3 weeks for 6 cycles

RADIATION

Intensity Modulated Radiotherapy Treatments

Total dose will be 60 Gray (Gy) at 2Gy per fractions for 30 fractions delivered Monday through Friday for 6 weeks

Trial Locations (3)

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

29425

Medical University of South Carolina - Hollings Cancer Center, Charleston

35294

University Of Alabama At Birmingham, Birmingham

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER